Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device

Version 1 : Received: 6 April 2022 / Approved: 8 April 2022 / Online: 8 April 2022 (03:27:23 CEST)
Version 2 : Received: 5 June 2022 / Approved: 6 June 2022 / Online: 6 June 2022 (05:53:21 CEST)

How to cite: Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069 (doi: 10.20944/preprints202204.0069.v2). Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069 (doi: 10.20944/preprints202204.0069.v2).

Abstract

Background: Transarterial chemoembolization (TACE) is the standard treatment for BCLC-B hepatocellular carcinoma (HCC). A novel glass membrane emulsification device (GMD) produces a high percentage of water/oil emulsions with homogeneous and stable droplets. There are few reports on the efficacy of GMD-conventional-TACE (GMD-c-TACE);therefore, we aimed to evaluate the effectiveness of GMD-c-TACE. Methods: Seventy-one patients with HCC with tumor diameter <5 cm who underwent c-TACE with and without GMD were included in this study to investigate local recurrence and hepatic functional reserve. Results: The local recurrence rates of TACE without GMD were 3.0% at 6 months, 16.7% at 12 months, and 35.0% at 18 months, around where it plateaued. Hence, the local recurrence rates in the GMD-c-TACE group were 7.7% at 14 months and 23.1% at 20 months, respectively. Thus, GMD-c-TACE had a significantly lower local recurrence. Multivariate analysis showed that GMD-c-TACE could suppress local recurrence and maintain hepatic reserve. Conclusions: GMD-c-TACE allows dense lipiodol accumulation in the tumor and attainment of good local control. Additionally, the inhibition of the release of anticancer drugs may maintain hepatic reserve. GMD-c-TACE is useful in preventing local recurrence and is expected to become the standard treatment form of c-TACE in the future.

Keywords

hepatocellular carcinoma; conventional transarterial chemoembolization; emulsion; lipiodol; glass membrane emulsification device

Subject

MEDICINE & PHARMACOLOGY, Gastroenterology

Comments (1)

Comment 1
Received: 6 June 2022
Commenter: Toru Ishikawa
Commenter's Conflict of Interests: Author
Comment: many contents have been changed
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.